QUESTIONSConference on Pricing and Reimbursement for Medical Devices (Medical Device)
Venue: BSG Conference Centre
Location: London, United Kingdom
| Event Date/Time: Apr 15, 2010 | End Date/Time: Apr 16, 2010 |
Report as SpamDescription
Pricing & Reimbursement for Medical Devices
Steering towards commercial success through value-based pricing and reimbursement
15th - 16th April 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
• Dr Dhinagar Subramanian, Associate Director - Global Health Economics and Reimbursement, Ethicon (Johnson and Johnson)
• Graham Stokoe, Senior Faculty Board Member, World Medical Device Organisation (WMDO)
• Manolis Karamalis, Reimbursement Director, Medtronic
• Oliver Mast, Head Global Reimbursement - Diabetes Care, Roche Diagnostics
• Nathalie Verin, Health Economics Manager, Boston Scientific
• Dr Frances Sutcliffe, Associate Director, Appraisals – CHTE, The National Institute for Health and Clinical Excellence (NICE)
• Dr. Gerald Schnell, Partner, Simon-Kucher & Partners
• Dr Geoff Wilson, Reimbursement Leader, EMEA, GE Healthcare
• Dr Nigel Sansom, Lead - Global Technology Horizon Scanning, NHS National Innovation Centre
Medical devices manufacturers require a more rigorous and strategic approach to safeguard product prices and prevent competition. Innovative manufacturers that have integrated their pricing and product strategies will achieve exceptional growth and profitability in this changing environment.
Pricing and Reimbursement for Medical Devices conference provides expertise on integrated pricing, reimbursement and health economics strategies, across a variety of technologies. Addressing the needs of medical technology manufacturers, health technology assessors (HTA) and diagnostics companies, the conference will feature cutting edge themes by industry experts on market-focussed intelligence and value-based models.
Take advantage of the networking opportunities and gain insights on:
• Evaluation of reimbursement mechanisms in the five major EU markets (France, Italy, Spain, Germany and UK)
• Opportunities to obtain higher reimbursement for innovative medical devices
• NICE health technology and device appraisals: Processes and people
• Developing a reimbursement strategy for introducing an innovative medical device into a prospective payment based system (DRG)
• Combining reimbursement and clinical expertise to realise clinical utility targets
• Market Access and funding for medical devices in Central Eastern Europe
• Maximising the value of CED from a device manufacturer perspective
• Assigning monetary value to innovative medical devices and diagnostic technologies
Who will attend?
VP’s, Directors, Managers, Consultants of:
• Pricing and Reimbursement
• Market Access
• Price Monitoring
• Health Economics
• Outcomes Research
• Commercial Pricing
• Finance
• International Trade and Market Policy
• Parallel Trade
• Payer Relations
• Business/Corporate Strategy
• Sales & Marketing
• Brand Management
• Operations
• Research and Development
• Regulatory Affairs
• Economics/Government/Public Affairs
• Contracts
• Legal
• Health Policy
Members of:
• Medical Devices & Diagnostic Companies
• Academics, Hospitals & Government Health Bodies
• Independent Health Economists & Patient Representatives
Day 1
Day One, Thursday 15 April 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Evaluation of the reimbursement landscape for medical devices
• Analyse how reimbursement mechanisms for medical devices vary significantly across markets
• Review of reimbursement mechanisms for the five major EU markets (France, Italy, Spain, Germany and UK)
• Opportunities to obtain higher reimbursement for innovative medical devices
• Future trends: Overall market drivers
Dr Geoff Wilson
Reimbursement Leader, EMEA
GE Healthcare
10:50 NICE health technology and device appraisals
• Processes and methods used for technology appraisal
• Introduction into making reimbursement decisions at NICE: Processes and people
• Demonstrating value and cost-effective methods
• Challenges when appraising medical devices
• Future of assessing medical technologies at NICE
Dr Frances Sutcliffe
Associate Director, Appraisals - CHTE
The National Institute for Health and Clinical Excellence (NICE)
11:30 Morning refreshments
11:50 Developing a reimbursement strategy for introducing an innovative medical device into a prospective payment based system (DRG)
• A decision framework for medical devices entering a DRG-based payment system
• Assessing alternative sources of funding
• What is the likelihood of having to undergo a HTA?
Graham Stokoe
Senior Faculty Board Member
World Medical Device Organisation (WMDO)
12.30 Reimbursement for medical devices in England: Payment by Results (PbR)
• Basic principles
• Funding for innovative medical devices: Could it be improved?
• Case-study: Cardiac rhythm management devices
Nathalie Verin
Health Economics Manager
Boston Scientific
13:10 Networking lunch
14.30 Reimbursement coverage with evidence development (CED): Case studies on medical devices from around the world and key learnings
• Why coverage with evidence development will be a powerful risk-sharing tool in the future
• Case studies from around the world on medical devices involving coverage subject to further evidence generation
• Key learnings
• Maximising the value of CED from a device manufacturer perspective
Dr Dhinagar Subramanian
Associate Director - Global Health Economics and Reimbursement
Ethicon (Johnson and Johnson)
15:10 Developing central EU medical devices reimbursement dossiers to optimise the chances of reimbursement and commercial success
• The case for a central EU medical device dossier
• Optimal structure of the dossier
• Essential data requirements and component parts of the dossier
• The commercial value of getting it right
Mark Ratcliffe
Co-founder
PHMR Consulting
15:50 Afternoon refreshments
16:10 Developing a successful reimbursement model for novel technologies
Mattias Kyhlstedt
CEO
Synergus
16:50 Impact of Medicare coverage and payment on access to medical devices and diagnostics
• Discuss how Medicare coverage and payment processes impact patient access to new, often costly therapies
• Provide recent case study examples
• Highlight health care reform efforts and the potential impact on reimbursement for medical devices
17:30 Closing remarks from the chair
17:35 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 2
Day Two, Friday 16 March 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Assigning monetary value to innovative medical devices and diagnostic technologies: A pragmatic approach to value-based pricing
• The case for value-based pricing for medical devices and diagnostics
• Can monetary value be ascertained for all innovations?
• Theoretical concepts and pragmatic approach to value-based pricing: Examples
• Value based-pricing in the product development process: How early?
Dr Dhinagar Subramanian
Associate Director - Global Health Economics and Reimbursement
Ethicon (Johnson and Johnson)
10:50 International price strategy for medical devices
• Recent observations on international price referencing and parallel trade
• Initial risk assessment for selected product groups
• How to cope with international price differentials
• Monitoring price developments in a global organisation
Dr. Gerald Schnell
Partner
Simon-Kucher & Partners
11:30 Morning refreshments
11:50 Market access and funding for medical devices in Central Eastern Europe
• Medical technology and health care systems in CEE
• Impact of financial crisis on health care environment in CEE
• HTA environment in CEE
Manolis Karamalis
Reimbursement Director
Medtronic
12:30 Market access for innovative devices
• What is perceived as an innovative product?
• Managing the challenges of innovation at the institutional EU level?
• How is innovation evaluated in terms of market price and incentives?
13:10 Networking lunch
14.30 Combining reimbursement and clinical expertise to realise clinical utility targets
• What do we understand of the terms “reimbursement†and “clinical utility�
• The changing face of procurement and pricing: 30 years of experience with medical devices
• Evidence-based medicine for medical devices
• New challenges for industry: 2010-2014
Mike Brough
Sales Director, CPB Division
Sorin Group
15:10 Medical Devices in HTA: A critical review of recent examples in diabetes care
• HTA challenge for medical devices: Common aspects and differences with pharmaceuticals
• One evidence base - many conclusions: Some examples
• RCTs or observational data: What is best?
• What to do when an HTA is on the agenda?
Oliver Mast
Head Global Reimbursement, Diabetes Care
Roche Diagnostics
15:50 Afternoon refreshments
16:10 Driving medical innovation through NHS Innovation pathway
• Economic benefits
• Awareness of the new technology
• Case studies
Dr Nigel Sansom
Lead - Global Technology Horizon Scanning
NHS National Innovation Centre
Michael Branagan-Harris
Director International Health Economics and Reimbursement - Vascular Therapies
Covidien
16.50 Development of clinical evidence for medical devices
• What types of evidence are necessary at each stage of market launch?
• Is level I clinical evidence a hurdle for market access?
• Discuss the gaps between HTA & P&R
17:30 Chair’s closing remarks
17:40 End of Conference
Related Reports:
Global Medical Devices Market 2008-2012
Medical Devices Market in Europe 2008-2012
Global and China Medical Devices Industry Report
Analysis report of the market research of medical devices in China in 2008 2010
Global Medical Devices Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
Steering towards commercial success through value-based pricing and reimbursement
15th - 16th April 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
• Dr Dhinagar Subramanian, Associate Director - Global Health Economics and Reimbursement, Ethicon (Johnson and Johnson)
• Graham Stokoe, Senior Faculty Board Member, World Medical Device Organisation (WMDO)
• Manolis Karamalis, Reimbursement Director, Medtronic
• Oliver Mast, Head Global Reimbursement - Diabetes Care, Roche Diagnostics
• Nathalie Verin, Health Economics Manager, Boston Scientific
• Dr Frances Sutcliffe, Associate Director, Appraisals – CHTE, The National Institute for Health and Clinical Excellence (NICE)
• Dr. Gerald Schnell, Partner, Simon-Kucher & Partners
• Dr Geoff Wilson, Reimbursement Leader, EMEA, GE Healthcare
• Dr Nigel Sansom, Lead - Global Technology Horizon Scanning, NHS National Innovation Centre
Medical devices manufacturers require a more rigorous and strategic approach to safeguard product prices and prevent competition. Innovative manufacturers that have integrated their pricing and product strategies will achieve exceptional growth and profitability in this changing environment.
Pricing and Reimbursement for Medical Devices conference provides expertise on integrated pricing, reimbursement and health economics strategies, across a variety of technologies. Addressing the needs of medical technology manufacturers, health technology assessors (HTA) and diagnostics companies, the conference will feature cutting edge themes by industry experts on market-focussed intelligence and value-based models.
Take advantage of the networking opportunities and gain insights on:
• Evaluation of reimbursement mechanisms in the five major EU markets (France, Italy, Spain, Germany and UK)
• Opportunities to obtain higher reimbursement for innovative medical devices
• NICE health technology and device appraisals: Processes and people
• Developing a reimbursement strategy for introducing an innovative medical device into a prospective payment based system (DRG)
• Combining reimbursement and clinical expertise to realise clinical utility targets
• Market Access and funding for medical devices in Central Eastern Europe
• Maximising the value of CED from a device manufacturer perspective
• Assigning monetary value to innovative medical devices and diagnostic technologies
Who will attend?
VP’s, Directors, Managers, Consultants of:
• Pricing and Reimbursement
• Market Access
• Price Monitoring
• Health Economics
• Outcomes Research
• Commercial Pricing
• Finance
• International Trade and Market Policy
• Parallel Trade
• Payer Relations
• Business/Corporate Strategy
• Sales & Marketing
• Brand Management
• Operations
• Research and Development
• Regulatory Affairs
• Economics/Government/Public Affairs
• Contracts
• Legal
• Health Policy
Members of:
• Medical Devices & Diagnostic Companies
• Academics, Hospitals & Government Health Bodies
• Independent Health Economists & Patient Representatives
Day 1
Day One, Thursday 15 April 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Evaluation of the reimbursement landscape for medical devices
• Analyse how reimbursement mechanisms for medical devices vary significantly across markets
• Review of reimbursement mechanisms for the five major EU markets (France, Italy, Spain, Germany and UK)
• Opportunities to obtain higher reimbursement for innovative medical devices
• Future trends: Overall market drivers
Dr Geoff Wilson
Reimbursement Leader, EMEA
GE Healthcare
10:50 NICE health technology and device appraisals
• Processes and methods used for technology appraisal
• Introduction into making reimbursement decisions at NICE: Processes and people
• Demonstrating value and cost-effective methods
• Challenges when appraising medical devices
• Future of assessing medical technologies at NICE
Dr Frances Sutcliffe
Associate Director, Appraisals - CHTE
The National Institute for Health and Clinical Excellence (NICE)
11:30 Morning refreshments
11:50 Developing a reimbursement strategy for introducing an innovative medical device into a prospective payment based system (DRG)
• A decision framework for medical devices entering a DRG-based payment system
• Assessing alternative sources of funding
• What is the likelihood of having to undergo a HTA?
Graham Stokoe
Senior Faculty Board Member
World Medical Device Organisation (WMDO)
12.30 Reimbursement for medical devices in England: Payment by Results (PbR)
• Basic principles
• Funding for innovative medical devices: Could it be improved?
• Case-study: Cardiac rhythm management devices
Nathalie Verin
Health Economics Manager
Boston Scientific
13:10 Networking lunch
14.30 Reimbursement coverage with evidence development (CED): Case studies on medical devices from around the world and key learnings
• Why coverage with evidence development will be a powerful risk-sharing tool in the future
• Case studies from around the world on medical devices involving coverage subject to further evidence generation
• Key learnings
• Maximising the value of CED from a device manufacturer perspective
Dr Dhinagar Subramanian
Associate Director - Global Health Economics and Reimbursement
Ethicon (Johnson and Johnson)
15:10 Developing central EU medical devices reimbursement dossiers to optimise the chances of reimbursement and commercial success
• The case for a central EU medical device dossier
• Optimal structure of the dossier
• Essential data requirements and component parts of the dossier
• The commercial value of getting it right
Mark Ratcliffe
Co-founder
PHMR Consulting
15:50 Afternoon refreshments
16:10 Developing a successful reimbursement model for novel technologies
Mattias Kyhlstedt
CEO
Synergus
16:50 Impact of Medicare coverage and payment on access to medical devices and diagnostics
• Discuss how Medicare coverage and payment processes impact patient access to new, often costly therapies
• Provide recent case study examples
• Highlight health care reform efforts and the potential impact on reimbursement for medical devices
17:30 Closing remarks from the chair
17:35 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Day 2
Day Two, Friday 16 March 2010
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Assigning monetary value to innovative medical devices and diagnostic technologies: A pragmatic approach to value-based pricing
• The case for value-based pricing for medical devices and diagnostics
• Can monetary value be ascertained for all innovations?
• Theoretical concepts and pragmatic approach to value-based pricing: Examples
• Value based-pricing in the product development process: How early?
Dr Dhinagar Subramanian
Associate Director - Global Health Economics and Reimbursement
Ethicon (Johnson and Johnson)
10:50 International price strategy for medical devices
• Recent observations on international price referencing and parallel trade
• Initial risk assessment for selected product groups
• How to cope with international price differentials
• Monitoring price developments in a global organisation
Dr. Gerald Schnell
Partner
Simon-Kucher & Partners
11:30 Morning refreshments
11:50 Market access and funding for medical devices in Central Eastern Europe
• Medical technology and health care systems in CEE
• Impact of financial crisis on health care environment in CEE
• HTA environment in CEE
Manolis Karamalis
Reimbursement Director
Medtronic
12:30 Market access for innovative devices
• What is perceived as an innovative product?
• Managing the challenges of innovation at the institutional EU level?
• How is innovation evaluated in terms of market price and incentives?
13:10 Networking lunch
14.30 Combining reimbursement and clinical expertise to realise clinical utility targets
• What do we understand of the terms “reimbursement†and “clinical utility�
• The changing face of procurement and pricing: 30 years of experience with medical devices
• Evidence-based medicine for medical devices
• New challenges for industry: 2010-2014
Mike Brough
Sales Director, CPB Division
Sorin Group
15:10 Medical Devices in HTA: A critical review of recent examples in diabetes care
• HTA challenge for medical devices: Common aspects and differences with pharmaceuticals
• One evidence base - many conclusions: Some examples
• RCTs or observational data: What is best?
• What to do when an HTA is on the agenda?
Oliver Mast
Head Global Reimbursement, Diabetes Care
Roche Diagnostics
15:50 Afternoon refreshments
16:10 Driving medical innovation through NHS Innovation pathway
• Economic benefits
• Awareness of the new technology
• Case studies
Dr Nigel Sansom
Lead - Global Technology Horizon Scanning
NHS National Innovation Centre
Michael Branagan-Harris
Director International Health Economics and Reimbursement - Vascular Therapies
Covidien
16.50 Development of clinical evidence for medical devices
• What types of evidence are necessary at each stage of market launch?
• Is level I clinical evidence a hurdle for market access?
• Discuss the gaps between HTA & P&R
17:30 Chair’s closing remarks
17:40 End of Conference
Related Reports:
Global Medical Devices Market 2008-2012
Medical Devices Market in Europe 2008-2012
Global and China Medical Devices Industry Report
Analysis report of the market research of medical devices in China in 2008 2010
Global Medical Devices Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
Venue
BSG Conference Centre, London, UK
MORE INFO ON THIS VENUE Restrictions
Invitation Only
